Related Experiment Video
Updated: Mar 31, 2026
Preparation of Oligomeric β-amyloid1-42 and Induction of Synaptic Plasticity Impairment on Hippocampal Slices
Published on: July 14, 2010
Aβ42-oligomer Interacting Peptide (AIP) neutralizes toxic amyloid-β42 species and protects synaptic structure and
Christian Barucker1, Heiko J Bittner2, Philip K-Y Chang1
1Department of Pharmacology and Therapeutics, Faculty of Medicine, McGill University, Montreal, QC, Canada.
Abstract:
The amyloid-β42 (Aβ42) peptide is believed to be the main culprit in the pathogenesis of Alzheimer disease (AD), impairing synaptic function and initiating neuronal degeneration. Soluble Aβ42 oligomers are highly toxic and contribute to progressive neuronal dysfunction, loss of synaptic spine density, and affect long-term potentiation (LTP). We have characterized a short, L-amino acid Aβ-oligomer Interacting Peptide (AIP) that targets a relatively well-defined population of low-n Aβ42 oligomers, rather than simply inhibiting the aggregation of Aβ monomers into oligomers. Our data show that AIP diminishes the loss of Aβ42-induced synaptic spine density and rescues LTP in organotypic hippocampal slice cultures. Notably, the AIP enantiomer (comprised of D-amino acids) attenuated the rough-eye phenotype in a transgenic Aβ42 fly model and significantly improved the function of photoreceptors of these flies in electroretinography tests. Overall, our results indicate that specifically "trapping" low-n oligomers provides a novel strategy for toxic Aβ42-oligomer recognition and removal.
Insights
A novel peptide, Aβ-oligomer Interacting Peptide (AIP), effectively targets toxic amyloid-β42 oligomers. This approach shows promise in protecting against Alzheimer disease-related neuronal damage and restoring synaptic function.
Area of Science:
- Neuroscience
- Molecular Biology
- Biochemistry
Background:
- Alzheimer disease (AD) pathogenesis is strongly linked to amyloid-β42 (Aβ42) peptide accumulation.
- Soluble Aβ42 oligomers are particularly toxic, causing synaptic dysfunction and neuronal loss.
Purpose of the Study:
- To characterize a novel peptide (AIP) designed to specifically target and interact with toxic low-n Aβ42 oligomers.
- To evaluate the therapeutic potential of AIP in models of Aβ42 toxicity.
Main Methods:
- Characterization of an L-amino acid Aβ-oligomer Interacting Peptide (AIP).
- Assessment of AIP's effect on Aβ42-induced synaptic spine density loss and long-term potentiation (LTP) in hippocampal slice cultures.
- Evaluation of the AIP enantiomer's efficacy in a transgenic Aβ42 fly model using electroretinography.
Main Results:
- AIP successfully diminished Aβ42-induced loss of synaptic spine density.
- AIP rescued long-term potentiation (LTP) in organotypic hippocampal slice cultures.
- The AIP enantiomer attenuated Aβ42-induced rough-eye phenotype and improved photoreceptor function in flies.
Conclusions:
- Targeting low-n Aβ42 oligomers with specific peptides like AIP represents a novel therapeutic strategy.
- AIP demonstrates potential for recognizing and removing toxic Aβ42 oligomers, offering a new avenue for Alzheimer disease treatment.
More Related Videos
06:17A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis
Published on: May 22, 2018
10:19Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps
Published on: August 14, 2016
Related Concept Videos
03:03Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
03:03Amyloid Fibrils
01:22Alzheimer's Disease: Treatment
01:26Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...